The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
March 1991 (Volume 69)
Quarterly Article
Robert A. Aronowitz
Nov 5, 2024
Oct 30, 2024
Oct 23, 2024
Back to The Milbank Quarterly
American medical researchers who investigated Lyme disease in the 1970s conceived of the disorder as a categorically new entity. Other interpretations emphasizing the continuities between Lyme disease and its epidemiological antecedents, nevertheless, were possible. Clinicians, patients, and advocacy groups continue to contest the character, significance, and appropriate treatment of Lyme disease. Highly publicized discussions among the interested parties reflect American society’s ongoing concern with new legitimating diagnoses, personal responsibility for acute and chronic disease, and the authority of science.
Author(s): Robert A. Aronowitz
Download the Article
Read on JSTOR
Volume 69, Issue 1 (pages 79–112) Published in 1991
